Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway

Jason T. Huse(The University of Texas MD Anderson Cancer Center), Matija Snuderl(NYU Langone Health), David Jones(German Cancer Research Center), Carole Brathwaite(Miami Children's Hospital), Nolan Altman(Miami Children's Hospital), Ehud Lavi(Cornell University), Richard Saffery(Royal Children's Hospital), Alexandra Sexton‐Oates(Royal Children's Hospital), Ingmar Blümcke(Friedrich-Alexander-Universität Erlangen-Nürnberg), David Capper(Heidelberg University), Matthias A. Karajannis(NYU Langone Health), Ryma Benayed(Memorial Sloan Kettering Cancer Center), Lukas Chávez(German Cancer Research Center), Cheddhi Thomas(NYU Langone Health), Jonathan Serrano(NYU Langone Health), Laetitia Borsu(Memorial Sloan Kettering Cancer Center), Marc Ladanyi(Memorial Sloan Kettering Cancer Center), Marc K. Rosenblum(Memorial Sloan Kettering Cancer Center)
Acta Neuropathologica
November 3, 2016
Cited by 259Open Access
Full Text

Abstract

Epileptogenic tumors affecting children and young adults are a morphologically diverse collection of neuroepithelial neoplasms that, as a group, exhibit varying levels of glial and/or neuronal differentiation. Recent advances in molecular profiling technology, including comprehensive DNA sequencing and methylation analysis, have enabled the application of more precise and biologically relevant classification schemes to these tumors. In this report, we describe a morphologically and molecularly distinct epileptogenic neoplasm, the polymorphous low-grade neuroepithelial tumor of the young (PLNTY), which likely accounts for a sizable portion of oligodendroglioma-like tumors affecting the pediatric population. Characteristic microscopic findings most notably include infiltrative growth, the invariable presence of oligodendroglioma-like cellular components, and intense immunolabeling for cluster of differentiation 34 (CD34). Moreover, integrative molecular profiling reveals a distinct DNA methylation signature for PLNTYs, along with frequent genetic abnormalities involving either B-Raf proto-oncogene (BRAF) or fibroblast growth factor receptors 2 and 3 (FGFR2, FGFR3). These findings suggest that PLNTY represents a distinct biological entity within the larger spectrum of pediatric, low-grade neuroepithelial tumors.


Related Papers